Black Diamond Therapeutics, Inc.
One Main Street
Cambridge
MA
02142
United States
Website: http://www.blackdiamondtherapeutics.com/
Email: info@bdtherapeutics.com
About Black Diamond Therapeutics, Inc.
Our Vision
Precision Cancer Medicines for Every Genetically-Defined Patient
Company Overview
Black Diamond Therapeutics: A Next-Wave Cancer Precision Medicine Company
Black Diamond Therapeutics has pioneered the development of selective medicines for patients with genetically-defined cancers driven by oncogenes activated by allosteric mutations.
The cornerstone of our approach derives from evolving trends in cancer clinical medicine. Genome-wide information – now routinely obtained from DNA testing of cancer patients – identifies clusters of uncharacterized genomic alterations. Today, new baskets of un-drugged oncogenic targets exist, leading to the identification of additional cancer patients in need of novel therapies.
Using our MAP platform, Black Diamond Therapeutics is pioneering new ways to functionally assess the mutational landscape of individual oncogenes – to discover and validate new targets, and to develop novel approaches to creating highly selective therapeutics.
89 articles with Black Diamond Therapeutics, Inc.
-
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
3/9/2023
Black Diamond Therapeutics, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a corporate update.
-
Black Diamond Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
2/27/2023
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023, at 12:50 p.m. ET in Boston, MA.
-
Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/5/2023
Black Diamond Therapeutics, Inc. announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 9:00 a.m. PT in San Francisco, California.
-
Black Diamond Therapeutics Announces Changes to Board of Directors
12/19/2022
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that Chairman of the Board of Directors, Robert (Bob) A. Ingram, has stepped down due to personal reasons. Existing Board member, Mark Velleca, M.D., Ph.D., has been appointed to succeed Mr. Ingram as the next Chairman.
-
Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company
12/12/2022
Black Diamond Therapeutics, Inc. today announced the formation of Launchpad Therapeutics, Inc.
-
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - November 09, 2022
11/9/2022
Black Diamond Therapeutics, Inc. announced that company management will participate in three upcoming investor conferences:
-
Black Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
11/8/2022
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
-
Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535 and BDTX-4933 at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
10/26/2022
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) today announced the presentation of three posters reporting new preclinical data on BDTX-1535 and BDTX-4933 at the 34th European Organisation for Research and Treatment of Cancer—National Cancer Institute—American Association for Cancer Research (EORTC-NCI-AACR) Symposium on Molecular Targets and Cancer Therapeutics being held in Barcelona, Spain.
-
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences in September 2022
9/6/2022
Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of Master Key therapies, announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the H.C. Wainwright 24th Annual Global Investment Conference.
-
Black Diamond Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8/9/2022
Black Diamond Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.
-
Black Diamond Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Virtual Conference
8/3/2022
Black Diamond Therapeutics, Inc. today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will participate in a panel discussion titled, Bullseye - Targeted Oncology - Quanta of Targets, at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022.
-
Black Diamond Therapeutics to Present at the Jefferies Global Healthcare Conference
6/6/2022
Black Diamond Therapeutics, Inc. announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the Jefferies Global Healthcare Conference on Wednesday, June 8, 2022, at 3:00pm ET in New York, NY.
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Black Diamond Therapeutics Appoints Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer
6/1/2022
Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, announced the appointment of Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer.
-
Black Diamond Therapeutics to Present at the H.C. Wainwright Global Investment Conference
5/17/2022
Black Diamond Therapeutics, Inc. announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the H.C. Wainwright Global Investment Conference.
-
Research Roundup: Stressing Cells May Mitigate Dementia and Another Clue to Parkinson's Disease
5/13/2022
Tangles of toxic proteins are associated with various dementias, such as Alzheimer's disease. Often, these tangles are misfolded proteins. Now, researchers have identified a new mechanism that might reverse the build-up of these aggregates. -
Black Diamond Therapeutics Announces Publication of New Computational and Functional Analyses of HER2 Mutations Based on its Proprietary MAP Discovery Engine
5/12/2022
Black Diamond Therapeutics, Inc. announced the publication of data identifying new oncogenic HER2 allosteric mutations that support the Mutation-Allostery-Pharmacology discovery engine’s capabilities and further suggest the need for novel inhibitors to treat HER2-mutant cancers.
-
Black Diamond Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/11/2022
Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
-
The first quarter hasn't been kind to international biopharmaceutical firms. BioSpace takes a look at the fates of Saniona and Black Diamond below.
-
Black Diamond Therapeutics Announces Pipeline Prioritization and Workforce Realignment
4/25/2022
Black Diamond Therapeutics, Inc. today announced that it is realigning its resources to focus on key near-term value drivers and to extend its cash runway into the third quarter of 2024, supporting the execution of important clinical and preclinical milestones.